SE9402510L - Förfarande för framställning av substituerade sulfoxider - Google Patents

Förfarande för framställning av substituerade sulfoxider

Info

Publication number
SE9402510L
SE9402510L SE9402510A SE9402510A SE9402510L SE 9402510 L SE9402510 L SE 9402510L SE 9402510 A SE9402510 A SE 9402510A SE 9402510 A SE9402510 A SE 9402510A SE 9402510 L SE9402510 L SE 9402510L
Authority
SE
Sweden
Prior art keywords
pct
date
sec
jul
single enantiomers
Prior art date
Application number
SE9402510A
Other languages
English (en)
Other versions
SE9402510D0 (sv
SE504459C2 (sv
Inventor
Magnus Larsson
Henrik Soerensen
Urban Stenhede
Unge Sverker Von
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20394753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9402510(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9402510A priority Critical patent/SE504459C2/sv
Publication of SE9402510D0 publication Critical patent/SE9402510D0/sv
Priority to AT95926068T priority patent/ATE242233T1/de
Priority to BR9508292A priority patent/BR9508292A/pt
Priority to US08/492,087 priority patent/US5948789A/en
Priority to AU29948/95A priority patent/AU688074B2/en
Priority to JP50493896A priority patent/JP3795917B2/ja
Priority to EP95926068A priority patent/EP0773940B2/en
Priority to DK95926068.8T priority patent/DK0773940T4/da
Priority to RU97102162/04A priority patent/RU2157806C2/ru
Priority to DE69530987T priority patent/DE69530987T3/de
Priority to UA97020638A priority patent/UA47409C2/uk
Priority to SK48-97A priority patent/SK284059B6/sk
Priority to CA002193994A priority patent/CA2193994C/en
Priority to PCT/SE1995/000818 priority patent/WO1996002535A1/en
Priority to EE9700006A priority patent/EE03354B1/xx
Priority to MX9700358D priority patent/MX9700358A/es
Priority to SI9530676T priority patent/SI0773940T2/sl
Priority to KR1019970700221A priority patent/KR100356252B1/ko
Priority to PT95926068T priority patent/PT773940E/pt
Priority to ES95926068T priority patent/ES2199998T5/es
Priority to TW084106875A priority patent/TW372971B/zh
Priority to CZ0006497A priority patent/CZ297987B6/cs
Priority to HU9700108A priority patent/HU226361B1/hu
Priority to NZ289959A priority patent/NZ289959A/en
Priority to PL95318165A priority patent/PL186342B1/pl
Priority to CN95194956A priority patent/CN1070489C/zh
Priority to IL11447795A priority patent/IL114477A/en
Priority to ZA955724A priority patent/ZA955724B/xx
Priority to MA23950A priority patent/MA23611A1/fr
Priority to DZ950088A priority patent/DZ1911A1/fr
Priority to EG57195A priority patent/EG24534A/xx
Priority to HR950401A priority patent/HRP950401B1/xx
Priority to TNTNSN95081A priority patent/TNSN95081A1/fr
Priority to YU47695A priority patent/YU49475B/sh
Priority to MYPI95001998A priority patent/MY113180A/en
Priority to TR95/00861A priority patent/TR199500861A2/xx
Priority to SA95160294A priority patent/SA95160294B1/ar
Publication of SE9402510L publication Critical patent/SE9402510L/sv
Priority to ARP960103398A priority patent/AR003443A1/es
Priority to IS4406A priority patent/IS1772B/is
Priority to FI970102A priority patent/FI117672B/sv
Priority to FI970102D priority patent/FI117830B/sv
Priority to NO19970153A priority patent/NO312101B1/no
Publication of SE504459C2 publication Critical patent/SE504459C2/sv
Priority to HK98109230A priority patent/HK1008331A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SE9402510A 1994-07-15 1994-07-15 Förfarande för framställning av substituerade sulfoxider SE504459C2 (sv)

Priority Applications (43)

Application Number Priority Date Filing Date Title
SE9402510A SE504459C2 (sv) 1994-07-15 1994-07-15 Förfarande för framställning av substituerade sulfoxider
PT95926068T PT773940E (pt) 1994-07-15 1995-07-03 Processo de sintese de sulfoxidos substituidos
ES95926068T ES2199998T5 (es) 1994-07-15 1995-07-03 Procedimiento para la síntesis de sulfóxidos sustituidos.
DE69530987T DE69530987T3 (de) 1994-07-15 1995-07-03 Verfahren zur herstellung von substituierten sulfoxiden
UA97020638A UA47409C2 (uk) 1994-07-15 1995-07-03 Спосіб синтезу заміщених сульфоксидів (варіанти) та сульфоксид
US08/492,087 US5948789A (en) 1994-07-15 1995-07-03 Process for synthesis of substituted sulphoxides
AU29948/95A AU688074B2 (en) 1994-07-15 1995-07-03 Process for synthesis of substituted sulphoxides
JP50493896A JP3795917B2 (ja) 1994-07-15 1995-07-03 置換スルホキシドの合成法
EP95926068A EP0773940B2 (en) 1994-07-15 1995-07-03 Process for synthesis of substituted sulphoxides
DK95926068.8T DK0773940T4 (da) 1994-07-15 1995-07-03 Fremgangsmåde til syntese af substituerede sulfoxider
RU97102162/04A RU2157806C2 (ru) 1994-07-15 1995-07-03 Способы синтеза замещенных сульфоксидов
AT95926068T ATE242233T1 (de) 1994-07-15 1995-07-03 Verfahren zur herstellung von substituierten sulfoxiden
BR9508292A BR9508292A (pt) 1994-07-15 1995-07-03 Processos para a sintese enãncio-seletiva de um composto,(-)-5-metóxi-2[[(4-metóxi-3,5-dimetil-2-piridinil) metil]sulfinil]-1h-benzimidazol,(+)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h-benzimidazol,(+)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h benzimidazol composto e uso dos compostos
SK48-97A SK284059B6 (sk) 1994-07-15 1995-07-03 Spôsob prípravy substituovaných sulfoxidov
CA002193994A CA2193994C (en) 1994-07-15 1995-07-03 Process for synthesis of substituted sulphoxides
PCT/SE1995/000818 WO1996002535A1 (en) 1994-07-15 1995-07-03 Process for synthesis of substituted sulphoxides
EE9700006A EE03354B1 (et) 1994-07-15 1995-07-03 Asendatud sulfoksiidide sünteesi protsess
MX9700358D MX9700358A (es) 1994-07-15 1995-07-03 Proceso par a la sintesis de sulfoxidos substituidos.
SI9530676T SI0773940T2 (sl) 1994-07-15 1995-07-03 Postopek za sintezo substituiranih sulfoksidov
KR1019970700221A KR100356252B1 (ko) 1994-07-15 1995-07-03 치환술폭시드의합성방법
TW084106875A TW372971B (en) 1994-07-15 1995-07-04 Process for synthesis of substituted sulphoxides
PL95318165A PL186342B1 (pl) 1994-07-15 1995-07-05 Sposób enancjoselektywnej syntezy związku sulfotlenkowego
HU9700108A HU226361B1 (en) 1994-07-15 1995-07-05 Process for synthesis of substituted sulphoxides
CZ0006497A CZ297987B6 (cs) 1994-07-15 1995-07-05 Zpusob prípravy substituovaných sulfoxidu
CN95194956A CN1070489C (zh) 1994-07-15 1995-07-05 取代的亚砜类化合物的合成方法
NZ289959A NZ289959A (en) 1994-07-15 1995-07-05 Process for enantioselective synthesis of substituted 2-[(2-pyridinyl(or phenyl)methyl)sulphinyl]-1h-[benzimidazole (or thienoimidazole)] (including omeprazole) and other structurally related suphoxides and salts thereof
IL11447795A IL114477A (en) 1994-07-15 1995-07-06 A process for the enantioselective synthesis of converted sulfoxides, individual enantiomers obtained as a result of the process and their use in the preparation of drugs
ZA955724A ZA955724B (en) 1994-07-15 1995-07-10 Process for synthesis of substituted sulphoxides
MA23950A MA23611A1 (fr) 1994-07-15 1995-07-10 Procede pour la synthese de sulfoxydes substitues
DZ950088A DZ1911A1 (fr) 1994-07-15 1995-07-11 Procédé pour la synthèse de sulfoxydes substitues.
EG57195A EG24534A (en) 1994-07-15 1995-07-11 Process for synthesis of substituted sulfoxides
HR950401A HRP950401B1 (en) 1994-07-15 1995-07-12 Process for synthesis of substituted sulphoxides
TNTNSN95081A TNSN95081A1 (fr) 1994-07-15 1995-07-13 Procede pour la synthese de sulfoxydes substitues
TR95/00861A TR199500861A2 (tr) 1994-07-15 1995-07-14 Ikame edilmis sulfoksidlerin sentezi icin proses.
YU47695A YU49475B (sh) 1994-07-15 1995-07-14 Postupak za sintezu supstituisanih sulfoksida
MYPI95001998A MY113180A (en) 1994-07-15 1995-07-14 Process for synthesis of substituted sulfoxides
SA95160294A SA95160294B1 (ar) 1994-07-15 1995-10-07 عملية لتحضير synthesisمركبات سلفوكسيد مستبدلة substituted sulphoxide
ARP960103398A AR003443A1 (es) 1994-07-15 1996-06-28 Procedimiento para la purificacion optica de preparaciones enantiomericamente enriquecidas de compuestos derivados de 2-sulfinil-bencimidazol
IS4406A IS1772B (is) 1994-07-15 1996-12-27 Aðferð við myndun útskiptra súlfoxíða
FI970102A FI117672B (sv) 1994-07-15 1997-01-10 Förfarande för syntetisering av substituerade sulfoxider
FI970102D FI117830B (sv) 1994-07-15 1997-01-10 Förfarande för syntetisering av substituerade sulfoxider
NO19970153A NO312101B1 (no) 1994-07-15 1997-01-14 Fremgangsmåte for syntese av substituerte sulfoksider, og slike produktforbindelser
HK98109230A HK1008331A1 (en) 1994-07-15 1998-07-17 Process for synthesis of substituted sulphoxides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402510A SE504459C2 (sv) 1994-07-15 1994-07-15 Förfarande för framställning av substituerade sulfoxider

Publications (3)

Publication Number Publication Date
SE9402510D0 SE9402510D0 (sv) 1994-07-15
SE9402510L true SE9402510L (sv) 1996-01-16
SE504459C2 SE504459C2 (sv) 1997-02-17

Family

ID=20394753

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9402510A SE504459C2 (sv) 1994-07-15 1994-07-15 Förfarande för framställning av substituerade sulfoxider

Country Status (42)

Country Link
US (1) US5948789A (sv)
EP (1) EP0773940B2 (sv)
JP (1) JP3795917B2 (sv)
KR (1) KR100356252B1 (sv)
CN (1) CN1070489C (sv)
AR (1) AR003443A1 (sv)
AT (1) ATE242233T1 (sv)
AU (1) AU688074B2 (sv)
BR (1) BR9508292A (sv)
CA (1) CA2193994C (sv)
CZ (1) CZ297987B6 (sv)
DE (1) DE69530987T3 (sv)
DK (1) DK0773940T4 (sv)
DZ (1) DZ1911A1 (sv)
EE (1) EE03354B1 (sv)
EG (1) EG24534A (sv)
ES (1) ES2199998T5 (sv)
FI (2) FI117672B (sv)
HK (1) HK1008331A1 (sv)
HR (1) HRP950401B1 (sv)
HU (1) HU226361B1 (sv)
IL (1) IL114477A (sv)
IS (1) IS1772B (sv)
MA (1) MA23611A1 (sv)
MX (1) MX9700358A (sv)
MY (1) MY113180A (sv)
NO (1) NO312101B1 (sv)
NZ (1) NZ289959A (sv)
PL (1) PL186342B1 (sv)
PT (1) PT773940E (sv)
RU (1) RU2157806C2 (sv)
SA (1) SA95160294B1 (sv)
SE (1) SE504459C2 (sv)
SI (1) SI0773940T2 (sv)
SK (1) SK284059B6 (sv)
TN (1) TNSN95081A1 (sv)
TR (1) TR199500861A2 (sv)
TW (1) TW372971B (sv)
UA (1) UA47409C2 (sv)
WO (1) WO1996002535A1 (sv)
YU (1) YU49475B (sv)
ZA (1) ZA955724B (sv)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
IL133800A0 (en) 1997-07-03 2001-04-30 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP2002501897A (ja) * 1998-01-30 2002-01-22 セプラコール， インク． Ｒ−ランソプラゾール組成物及び方法
WO1999055157A1 (en) * 1998-04-30 1999-11-04 Sepracor Inc. R-rabeprazole compositions and methods
JP2002512263A (ja) * 1998-04-30 2002-04-23 セプラコール， インク． Ｓ−レイブプラゾール組成物及び方法
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CN1087739C (zh) * 1998-12-28 2002-07-17 中国科学院成都有机化学研究所 光学纯的苯并咪唑类抗消化性溃疡药物的包结拆分制备法
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
EP1191025B1 (en) * 1999-06-30 2005-06-22 Takeda Pharmaceutical Company Limited Crystals of lansoprazole
WO2001014366A1 (fr) * 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Procede de preparation de derives optiquement actifs de sulfoxyde
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
CA2407208C (en) * 2000-04-28 2010-08-17 Takeda Chemical Industries, Ltd. Process for producing optically active sulfoxide derivative
KR100869677B1 (ko) 2000-05-15 2008-11-21 다케다 야쿠힌 고교 가부시키가이샤 결정의 제조방법
ES2511774T3 (es) 2000-05-15 2014-10-23 Takeda Pharmaceutical Company Limited Formas cristalinas de (R)-lansoprazol
WO2002012225A1 (fr) 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Sels de composé à base de benzimidazole et leurs applications
HU229356B1 (en) * 2000-12-01 2013-11-28 Takeda Pharmaceutical Process for the crystallization of (r)- or (s)-lansoprazole
JP2004536049A (ja) * 2001-04-13 2004-12-02 アプシンターム・リミテッド・ライアビリティ・カンパニー スルフィンアミドおよびスルホキシドの製造方法
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
ES2286408T3 (es) 2002-03-05 2007-12-01 Astrazeneca Ab Sales de alquilamonio de omeprazol e esomeprazol.
AU2003262375A1 (en) * 2002-04-22 2003-11-03 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
US7169793B2 (en) 2002-06-27 2007-01-30 Dr. Reddy's Laboratories Limited Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
ES2534713T3 (es) * 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
US20040235903A1 (en) 2002-10-22 2004-11-25 Khanna Mahavir Singh Amorphous form of esomeprazole salts
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
US7301030B2 (en) * 2002-12-06 2007-11-27 Nycomed Gmbh Process for preparing (S)-pantoprazole
NZ540815A (en) * 2002-12-06 2008-03-28 Nycomed Gmbh Process for preparing optically pure active compounds
AR046245A1 (es) * 2002-12-16 2005-11-30 Ranbaxy Lab Ltd Sales de calcio de rabeprazol
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
US7507829B2 (en) 2002-12-19 2009-03-24 Teva Pharmaceuticals Industries, Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
EP1583507A2 (en) * 2003-01-07 2005-10-12 Ranbaxy Laboratories Limited Magnesium salt of imidazole derivative
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
CN1777598A (zh) * 2003-02-28 2006-05-24 兰贝克赛实验室有限公司 S－奥美拉唑的多晶型物
ES2245277T1 (es) * 2003-03-12 2006-01-01 Teva Pharmaceutical Industries Limited Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
EP1611901B1 (en) * 2003-03-13 2013-07-10 Eisai R&D Management Co., Ltd. Preventive or remedy for teeth grinding
FR2852956B1 (fr) * 2003-03-28 2006-08-04 Negma Gild Procede de preparation enantioselective de derives de sulfoxydes
WO2004087702A2 (fr) * 2003-03-28 2004-10-14 Sidem Pharma Procede de preparation enantioselective de derives de sulfoxydes.
EP1633736A1 (en) * 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
MXPA05013316A (es) 2003-06-10 2006-03-17 Teva Pharma Proceso para preparar bencimidazoles 2[-(piridinil)metil]sulfinil-sustituidos y derivados clorados novedosos de pantoprazol.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
AU2003288703A1 (en) * 2003-12-05 2005-06-24 Hetero Drugs Limited A process for the preparation of substitited pyridinylmethylsulfinyl- benzimidazole enantiomers
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
PT1740571E (pt) 2004-04-28 2009-09-02 Hetero Drugs Ltd Processo para preparar compostos de piridinilmetil-1hbenzimidazol na forma enantiomericamente enriquecida ou como enantiómeros únicos
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE602004025386D1 (de) * 2004-05-28 2010-03-18 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
BRPI0511515A (pt) * 2004-06-02 2007-12-26 Altana Pharma Ag processo para a preparação de compostos de piridin-2-ilmetilsulfinil-1h-benzimidazol
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
KR20130038949A (ko) * 2004-06-24 2013-04-18 아스트라제네카 아베 에소메프라졸 나트륨염의 제조에서 사용하기 위한 결정 변형의 제조를 위한 신규한 방법
WO2006001755A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab A new esomeprazole sodium salt crystal modification
FR2876101B1 (fr) * 2004-10-05 2007-03-02 Sidem Pharma Sa Sa Procede de preparation enantioselective de derives de sulfoxydes
WO2006040635A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited Processes for the preparation of substituted sulfoxides
US7592111B2 (en) * 2004-11-05 2009-09-22 Xerox Corporation Imaging member
WO2006099810A1 (en) 2005-03-25 2006-09-28 Livzon Pharmaceutical Group Inc. Substituted sulfoxide compounds, methods for preparing the same and use thereof
CN101098867B (zh) * 2005-03-25 2010-08-11 丽珠医药集团股份有限公司 取代的亚砜类化合物和其制备方法及用途
KR20080007508A (ko) * 2005-05-06 2008-01-21 그렌마크 파머수티칼스 엘티디. 에소메프라졸 스트론튬염, 그것의 제조방법 및 그것을함유하는 약제학적 조성물
WO2006131338A2 (en) * 2005-06-08 2006-12-14 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
CN101321746A (zh) * 2005-12-05 2008-12-10 阿斯利康(瑞典)有限公司 制备艾美拉唑非盐形式的新方法
DE102005061720B3 (de) * 2005-12-22 2006-10-19 Ratiopharm Gmbh Enantioselektive Herstellung von Benzimidazolderivaten und ihren Salzen
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
WO2007074099A1 (en) 2005-12-28 2007-07-05 Unión Químico Farmacéutica, S.A. A process for the preparation of the (s)-enantiomer of omeprazole
CN1810803B (zh) * 2006-02-17 2010-11-17 中国科学院上海有机化学研究所 高对映体选择性制备(s)-奥美拉唑的方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US7786309B2 (en) * 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
MY148301A (en) 2006-07-05 2013-03-29 Lupin Ltd Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds
US8173818B2 (en) 2006-08-08 2012-05-08 Jubilant Organosys Limited Process for producing sulphoxide compounds
US20110009624A9 (en) 2006-10-13 2011-01-13 Masato Ueda Benzimidazole compounds having gastric acid secretion inhibitory action
JP2009196894A (ja) * 2006-10-13 2009-09-03 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物またはその塩の製造方法
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
NZ579136A (en) 2007-02-21 2012-05-25 Cipla Ltd Process for the preparation of esomeprazole magnesium dihydrate
WO2008149204A1 (en) * 2007-06-07 2008-12-11 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
US20100210848A1 (en) * 2007-10-03 2010-08-19 Ipca Laboratories Ltd. Process for optically active sulfoxide compounds
WO2009047775A2 (en) 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
JP5629581B2 (ja) 2007-10-12 2014-11-19 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド 食物の摂取から独立した消化器疾患の治療方法
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
CN101492459B (zh) * 2008-01-25 2011-04-27 山东轩竹医药科技有限公司 含烷氧乙酰基二氢异噁唑并吡啶化合物
CN101497603B (zh) * 2008-01-30 2012-11-07 山东轩竹医药科技有限公司 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
UA103189C2 (ru) 2008-03-10 2013-09-25 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма бензимидазольного соединения
EP2265605A4 (en) * 2008-03-18 2011-08-03 Reddys Lab Ltd Dr METHOD OF MANUFACTURING DEXLANSOPRAZOLE AND POLYMORPHIDE THEREOF
CN101538264A (zh) * 2008-03-19 2009-09-23 中国科学院成都有机化学有限公司 手性亚砜类化合物的制备新方法
WO2009145368A1 (en) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
IT1391776B1 (it) 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
CZ200990A3 (cs) * 2009-02-16 2010-08-25 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CZ2009172A3 (cs) * 2009-03-17 2010-09-29 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
EP2438057A4 (en) * 2009-06-02 2013-12-25 Sun Pharmaceutical Ind Ltd PROCESS FOR PREPARING SULFOXIDE COMPOUNDS
IT1395118B1 (it) 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
EP2499125B1 (en) 2009-11-12 2016-01-27 Hetero Research Foundation Process for the resolution of omeprazole
WO2011092665A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
EP2585450A1 (en) 2010-06-24 2013-05-01 Cilpa Limited Salts and polymorphs of dexrabeprazole
CN101914090B (zh) * 2010-08-13 2013-03-20 埃斯特维华义制药有限公司 左旋奥美拉唑的制备方法
CN102558150B (zh) * 2010-12-31 2014-03-12 正大天晴药业集团股份有限公司 取代亚砜化合物的合成方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN102977076A (zh) * 2011-09-02 2013-03-20 扬子江药业集团上海海尼药业有限公司 一种右兰索拉唑的制备方法
CN102329302A (zh) * 2011-10-22 2012-01-25 刘强 一种埃索美拉唑及其盐的制备方法
CN102408412A (zh) * 2011-10-25 2012-04-11 广东华南药业集团有限公司 高对映体选择性制备（s）- 奥美拉唑的方法
CN102432412A (zh) * 2011-10-28 2012-05-02 成都欣捷高新技术开发有限公司 一种手性亚砜类质子泵抑制剂或其可药用盐的制备方法
KR101300950B1 (ko) * 2011-10-31 2013-08-27 르노삼성자동차 주식회사 전기자동차의 공기 흡입 장치
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
CN102659763B (zh) * 2012-04-27 2014-01-22 南京优科生物医药研究有限公司 一种右旋兰索拉唑合成与纯化的方法
CN103044402B (zh) * 2012-12-31 2015-01-14 康普药业股份有限公司 埃索美拉唑钠合成生产方法
CN103113351B (zh) * 2013-03-08 2015-01-21 苏州特瑞药业有限公司 一种光学纯手性亚砜类化合物的制备方法
CN104177336A (zh) * 2013-05-28 2014-12-03 上海汇伦生命科技有限公司 一种对映选择性合成右兰索拉唑的方法
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
WO2015155281A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
EP2980086B1 (en) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of esomeprazole (S)-binol complex
EP3239146A4 (en) * 2014-12-26 2018-05-30 The University of Tokyo Method for producing proton pump inhibitor compound having optical activity
CN104610226A (zh) * 2014-12-31 2015-05-13 广东东阳光药业有限公司 一种右兰索拉唑的不对称氧化方法
EP3064495B1 (en) 2015-03-06 2016-12-14 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of optically pure esomeprazole
CN105218392B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 D‑酒石酸单酯单酰胺类化合物
CN105218391B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 L‑酒石酸单酯单酰胺类化合物
CN105968097B (zh) * 2016-05-17 2019-05-03 杭州华东医药集团新药研究院有限公司 左旋泮托拉唑的工业化生产方法
CN106083818A (zh) * 2016-06-08 2016-11-09 扬子江药业集团有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106366070B (zh) * 2016-08-10 2019-06-11 上海万巷制药有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106632249A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种制备(s)‑泮托拉唑钠的方法
CN106632248A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种左旋泮托拉唑钠的制备工艺
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN110746428A (zh) * 2019-10-29 2020-02-04 株洲千金药业股份有限公司 一种r型手性亚砜类化合物的制备方法
CN110698482A (zh) * 2019-10-29 2020-01-17 株洲千金药业股份有限公司 一种s型手性亚砜类化合物的制备方法
CN113845510A (zh) * 2020-06-27 2021-12-28 鲁南制药集团股份有限公司 一种埃索美拉唑的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution

Also Published As

Publication number Publication date
SK284059B6 (sk) 2004-09-08
HUT76642A (en) 1997-10-28
YU47695A (sh) 1998-07-10
DZ1911A1 (fr) 2002-02-17
AU2994895A (en) 1996-02-16
NO970153D0 (no) 1997-01-14
NO970153L (no) 1997-01-14
FI117830B (sv) 2007-03-15
SA95160294B1 (ar) 2006-07-31
RU2157806C2 (ru) 2000-10-20
HRP950401A2 (en) 1997-10-31
EP0773940A1 (en) 1997-05-21
NZ289959A (en) 1998-01-26
CN1070489C (zh) 2001-09-05
EP0773940B1 (en) 2003-06-04
CZ297987B6 (cs) 2007-05-16
HK1008331A1 (en) 1999-05-07
PL318165A1 (en) 1997-05-26
JPH10504290A (ja) 1998-04-28
ES2199998T5 (es) 2011-03-16
CA2193994A1 (en) 1996-02-01
DE69530987T3 (de) 2011-07-07
MX9700358A (es) 1997-04-30
UA47409C2 (uk) 2002-07-15
EE03354B1 (et) 2001-02-15
TR199500861A2 (tr) 1996-06-21
SE9402510D0 (sv) 1994-07-15
DK0773940T3 (da) 2003-09-15
HU226361B1 (en) 2008-09-29
CN1157614A (zh) 1997-08-20
IS4406A (is) 1996-12-27
AU688074B2 (en) 1998-03-05
FI970102A (sv) 1997-01-10
PL186342B1 (pl) 2003-12-31
DE69530987D1 (de) 2003-07-10
ZA955724B (en) 1996-01-15
SI0773940T2 (sl) 2011-02-28
EG24534A (en) 2009-08-30
US5948789A (en) 1999-09-07
BR9508292A (pt) 1997-12-23
AR003443A1 (es) 1998-08-05
TNSN95081A1 (fr) 1996-02-06
EP0773940B2 (en) 2010-11-17
KR100356252B1 (ko) 2002-11-18
MA23611A1 (fr) 1996-04-01
MY113180A (en) 2001-12-31
NO312101B1 (no) 2002-03-18
JP3795917B2 (ja) 2006-07-12
CA2193994C (en) 2005-05-03
DE69530987T2 (de) 2004-05-19
YU49475B (sh) 2006-05-25
SE504459C2 (sv) 1997-02-17
WO1996002535A8 (en) 1999-12-23
KR970704731A (ko) 1997-09-06
WO1996002535A1 (en) 1996-02-01
IS1772B (is) 2001-06-01
SK4897A3 (en) 1997-08-06
CZ6497A3 (en) 1997-06-11
IL114477A (en) 2001-07-24
FI970102A0 (sv) 1997-01-10
PT773940E (pt) 2003-10-31
HRP950401B1 (en) 2004-04-30
FI117672B (sv) 2007-01-15
IL114477A0 (en) 1995-11-27
TW372971B (en) 1999-11-01
ES2199998T3 (es) 2004-03-01
ATE242233T1 (de) 2003-06-15
SI0773940T1 (en) 2004-02-29
DK0773940T4 (da) 2011-02-07

Similar Documents

Publication Publication Date Title
SE9402510L (sv) Förfarande för framställning av substituerade sulfoxider
DE69529686D1 (de) Enantiosektive herstellung pharmazeutisch aktiver sulfoxide durch biooxidation
FR2692264B1 (fr) Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
NO972912D0 (no) Fremstilling av tabletter som kan deles
FI20030932A (sv) Förfarande för upplösning av cis-enatiomerer av FTC
DE69525840T2 (de) Herstellung von arthropodiziden oxadiazinen
IL116385A (en) Sulphonamides their manufacture and pharmaceutical compositions containing them
FI792149A (fi) (d1)-16-fenoxi- och 16-substituerad-fenoxi-9-keto-prostatriensyraderivat och foerfarande foer deras framstaellning
FI952677A (sv) Förfarande för framställning av väsentligen rena enantiomerer av fenylpropionsyra
DE69525950T2 (de) Racemisierungsverfahren bei der herstellung von levobupivacaine und analogen
HU9802206D0 (en) Intravenous thaidomid composition for treating immunological diseases
ES2108595A1 (es) Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion.
FR2663328B1 (fr) Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
DE69604054D1 (de) Herstellung von mit enantiomer angereicherten ortho-substituierten alpha, alpha-diaromatischen methanolen
ATE127465T1 (de) Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen.
KR890006621A (ko) 항불안제
ATE216702T1 (de) Silylierungsprocess
ATE73792T1 (de) Annaeherung zur herstellung von natuerlicher vitamin e verwendender asymetrischer synthese.
ATE399876T1 (de) Chemoenzymatisches verfahren zur stereoselektiven herstellung von optisch-angereicherten phenylglycidate
ATE78060T1 (de) Stereospezifische ketoreduktion von bicyclooctandion-carbonsaeureestern durch mikroorganismen.
ATE295728T1 (de) Herstellung von 3-fluoroxindolderivaten
TH23382A (th) กรรมวิธีสำหรับสังเคราะห์ซับสทิทิวเทดซัลฟอกไซด์
DK0868181T3 (da) Anvendelse af alfa,alfa-diphenyleddikesyre-4-(N-methyl-piperidyl)-estere som spasmoanalgetikum
NO972291L (no) Fremgangsmåte for fremstilling av optisk aktive forbindelser
DE69420276T2 (de) Cycloalkanediole und ihre verwendung zur herstellung von chiralen verbindungen

Legal Events

Date Code Title Description
NUG Patent has lapsed